Evidence map›Paper›PMID 37063876›Full record

ArticleFrontiers in immunology2023

Identification and validation of hub genes in drug induced acute kidney injury basing on integrated transcriptomic analysis.

Yi-Xuan Deng, Kun Liu, Qun-Xiang Qiu, Zhi-Yao Tang, Rui-Man Que, Dian-Ke Li, Xu-Rui Gu, Guang-Liang Zhou, Yi-Feng Wu, Ling-Yun Zhou and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. An HRedox biology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yi-Xuan DengDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Kun LiuDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Qun-Xiang QiuDepartment of Hematology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhi-Yao TangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Rui-Man QueDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Dian-Ke LiDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Xu-Rui GuDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Guang-Liang ZhouDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Yi-Feng WuDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Ling-Yun ZhouDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Wen-Jun YinDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Xiao-Cong ZuoDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
Third Xiangya Hospital · CNCentral South University · CNChongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Drug-induced acute kidney damage (DI-AKI) is a clinical phenomenon of rapid loss of kidney function over a brief period of time as a consequence of the using of medicines. The lack of a specialized treatment and the instability of traditional kidney injury markers to detect DI-AKI frequently result in the development of chronic kidney disease. Thus, it is crucial to continue screening for DI-AKI hub genes and specific biomarkers. Methods: Differentially expressed genes (DEGs) of group iohexol, cisplatin, and vancomycin's were analyzed using Limma package, and the intersection was calculated. DEGs were then put into String database to create a network of protein-protein interactions (PPI). Ten algorithms are used in the Cytohubba plugin to find the common hub genes. Three DI-AKI models' hub gene expression was verified Results: 95 up-regulated common DEGs and 32 down-regulated common DEGs were obtained using Limma package. A PPI network with 84 nodes and 24 edges was built with confidence >0.4. Four hub genes were obtained by Algorithms of Cytohubba plugin, including TLR4, AOC3, IRF4 and TNFAIP6. Then, we discovered that the protein and mRNA levels of four hub genes were significantly changed in the DI-AKI model Conclusion: The immune system and inflammation are key factors in DI-AKI. We discovered the immunological and inflammatory-related genes TLR4, AOC3, IRF4, and TNFAIP6, which may be promising specific biomarkers and essential hub genes for the prevention and identification of DI-AKI.

Indexed as

Acute Kidney InjuryToll-Like Receptor 4AnimalsAristolochic AcidsMiceTranscriptomeVancomycinaristolochic acid IAristolochic AcidsToll-Like Receptor 4Vancomycindrug-induced acute kidney injuryhub genesin vitro and in vivo validationLimma packageweighted gene co-expression network analysis

Identifiers

PMID37063876
PMCPMC10090697
OpenAlexW4361283935

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.